阿帕替尼在肺癌中的应用及研究进展

Research progress in the treatment of lung cancer with apatinib

近年来,肺癌的发病率及死亡率居高不下,成为癌症死亡的主要原因之一。当前,对晚期肺癌患者主要以化疗及靶向药物治疗为主,但是二线治疗进展后可供选择的药物很少。阿帕替尼是一种新型小分子酪氨酸激酶抑制剂,是中国研发的第1代口服抗血管生成药物,通过抑制多种信号转导通路,抑制血管生成,进而控制肿瘤发生,延长晚期肺癌患者的无进展生存期(Progression free survival,PFS)和总生存期(Overall survival,OS),已成为晚期肺癌化疗或其他靶向治疗失败后的一种选择。本文旨在回顾性研究国内外关于阿帕替尼的作用机制、在不同类型肺癌中的有效性、不良反应、最新进展等,以期能为肺癌的临床治疗提供帮助。

Lung cancer is one of the leading causes of cancer death worldwide and its morbidity and mortality remains high.Currently,chemotherapy and targeted drug therapy are the main treatments for patients with advanced lung cancer.However,few drugs could be selected when diseases progressed after second-line treatment.Apatinib(YN968 D1),a new small-molecular tyrosine kinase inhibitor,is the first generation of oral antiangiogenic drugs developed in China.By inhibiting several signaling transduction pathways,it restrains angiogenesis and subsequently controls tumorigenesis.According to current studies,apatinib can significantly prolong the progression-free survival(PFS)and overall survival(OS)of patients with advanced lung cancer.So,it might be an optional choice for advanced lung cancer after failure of chemotherapy or other targeted therapies.This study is to summarize the recent researches on apatinib,including the mechanism,effectiveness,adverse reactions and the latest progress,in order to provide references for future clinical practice in therapeutic options for lung cancer patients.